• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Emerg Infect Dis . Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity

tetano

Editor, Senior Moderator
Emerg Infect Dis


. 2020 Jun 16;26(9).
doi: 10.3201/eid2609.201840. Online ahead of print.
Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity

Hannah Clapham, James Hay, Isobel Routledge, Saki Takahashi, Marc Choisy, Derek Cummings, Bryan Grenfell, C Jessica E Metcalf, Michael Mina, Isabel Rodriguez Barraquer, Henrik Salje, Clarence C Tam

Abstract

Serologic studies are crucial for clarifying dynamics of the coronavirus disease pandemic. Past work on serologic studies (e.g., during influenza pandemics) has made relevant contributions, but specific conditions of the current situation require adaptation. Although detection of antibodies to measure exposure, immunity, or both seems straightforward conceptually, numerous challenges exist in terms of sample collection, what the presence of antibodies actually means, and appropriate analysis and interpretation to account for test accuracy and sampling biases. Successful deployment of serologic studies depends on type and performance of serologic tests, population studied, use of adequate study designs, and appropriate analysis and interpretation of data. We highlight key questions that serologic studies can help answer at different times, review strengths and limitations of different assay types and study designs, and discuss methods for rapid sharing and analysis of serologic data to determine global transmission of severe acute respiratory syndrome coronavirus 2.

Keywords: COVID-19; SARS-CoV-2; coronavirus disease; immunity; respiratory infections; seroepidemiologic; severe acute respiratory syndrome coronavirus 2; study design; viruses; zoonoses
 
Back
Top Bottom